The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SBFM | -56.33% | -99.98% | -81.87% | -100% |
| S&P | +15.66% | +86.6% | +13.29% | +567% |
Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product include treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Pointe-Claire, Canada.
No news articles found for Sunshine Biopharma.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $9.42M | 11.6% |
| Gross Profit | $2.98M | 6.3% |
| Gross Margin | 31.62% | -1.6% |
| Market Cap | $6.79M | 74.4% |
| Market Cap / Employee | $130.55K | 0.0% |
| Employees | 52 | 18.2% |
| Net Income | -$883.82K | 26.2% |
| EBITDA | -$436.14K | 58.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.31M | -23.8% |
| Accounts Receivable | $4.16M | 29.1% |
| Inventory | 14.1 | 43.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $636.71K | 44.6% |
| Short Term Debt | $218.05K | 87.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -19.47% | -4.8% |
| Return On Invested Capital | 9399.09% | -33.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$735.84K | 60.8% |
| Operating Free Cash Flow | -$727.80K | 46.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.24 | 0.21 | 0.17 | 0.26 | 66.81% |
| Price to Sales | 0.22 | 0.14 | 0.18 | 0.18 | 48.72% |
| Price to Tangible Book Value | 0.27 | 0.24 | 0.20 | 0.29 | 65.42% |
| Enterprise Value to EBITDA | 0.50 | 1.63 | 3.14 | 3.78 | -48.18% |
| Return on Equity | -23.0% | -21.2% | -25.6% | -24.3% | 35.37% |
| Total Debt | $952.48K | $936.18K | $929.03K | $854.76K | 53.58% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
